Implantable technology could enable in vivo CAR T therapy
Pre-clinical research demonstrates the potential of a new implantable biotechnology called MASTER to produce and release CAR T cells in vivo.
Stay updated with breaking news from Pritha Agarwalla. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pre-clinical research demonstrates the potential of a new implantable biotechnology called MASTER to produce and release CAR T cells in vivo.
Researchers have developed a marshmallow-like implant that can train a patient’s immune system to fight off cancer. In tests in mice, the technique was more effective against cancer and could be enacted much faster than other immunotherapies.
A team of North Carolina scientists, with early grant support from NCBiotech, has developed an implantable scaffold resembling a “mini marshmallow” that produces and releases CAR-T cells for attacking cancerous tumors.
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T cells for attacking cancerous tumors.
MASTER scaffolds carry out T-cell activation, reprogramming, and expansion inside the patient, transforming a multi-week process into a single-day procedure.